scholarly journals The serum level of CC chemokine ligand 18 correlates with the prognosis of non-small cell lung cancer

2019 ◽  
Vol 34 (2) ◽  
pp. 156-162 ◽  
Author(s):  
Hui Huang ◽  
Jing Li ◽  
Wen-jia Hu ◽  
Chen Chen ◽  
Hai-qing Luo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Serum Level ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Enzyme Linked Immunosorbent Assay ◽  
Small Cell Lung ◽  
Cc Chemokine ◽  
Chemokine Ligand ◽  
Nsclc Patients

Background: CC chemokine ligand 18 (CCL18) is a chemotactic cytokine involved in the pathogenesis and progression of various cancers. Our previous research showed that the expression of CCL18 is obviously higher in non-small cell lung cancer (NSCLC) than in the adjacent normal tissues, suggesting its role in NSCLC. Methods: We further examined the serum level of CCL18 in 80 NSCLC patients with enzyme-linked immunosorbent assay and simultaneously analyzed the survival curve of these patients by the Kaplan–Meier method, and then utilized a log-rank test to evaluate the correlation of CCL18 expression with the malignant progression of NSCLC. Results: Our results showed that the median serum concentration of CCL18 was significantly elevated to 436.11 ng/mL in NSCLC patients compared to 41.97 ng/ml in healthy people ( P<0.01), which was also positively related to the expression of lung cancer biomarkers carcinoma–embryonic antigen and cytokeratin fragment antigen 21-1. Moreover, correlation analysis showed that an increased level of serum CCL18 was associated with a worse survival time in NSCLC patients. Conclusion: Our findings suggest that the serum CCL18 level of NSCLC patients was negatively correlated with the prognosis, thus suggesting that CCL18 may serve as a potential circulating biomarker for NSCLC diagnosis.

scholarly journals Serum Level of CC-Chemokine Ligand 18 Is Increased in Patients with Non-Small-Cell Lung Cancer and Correlates with Survival Time in Adenocarcinomas

PLoS ONE ◽  
2012 ◽  
Vol 7 (7) ◽  
pp. e41746 ◽  
Author(s):  
Till Plönes ◽  
Alexander Krohn ◽  
Meike Burger ◽  
Hendrik Veelken ◽  
Bernward Passlick ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Serum Level ◽  
Small Cell Lung Cancer ◽  
Survival Time ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cc Chemokine ◽  
Chemokine Ligand

59PD SERUM LEVEL OF CC-CHEMOKINE LIGAND 18 (PULMONARY ACTIVATION-REGULATED CHEMOKINE) IN PATIENTS WITH NON SMALL CELL LUNG CANCER

Lung Cancer ◽  
2011 ◽  
Vol 71 ◽  
pp. S31
Author(s):  
T. Pl¨ones ◽  
U. M¨uller-Quernheim ◽  
M. Burger ◽  
H. Veelken ◽  
B. Passlick ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Serum Level ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cc Chemokine ◽  
Chemokine Ligand

scholarly journals Decreased IL-27 Negatively Correlated with Th17 Cells in Non-Small-Cell Lung Cancer Patients

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Minchao Duan ◽  
Zhengqing Ning ◽  
Zhijun Fu ◽  
Jianquan Zhang ◽  
Guangnan Liu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Peripheral Blood ◽  
Th17 Cells ◽  
Quantitative Polymerase Chain Reaction ◽  
Small Cell ◽  
Enzyme Linked Immunosorbent Assay ◽  
Small Cell Lung ◽  
Nsclc Patients

The presence of Th17 cells and IL-27 is observed in a variety of inflammatory associated cancers. However, there are some data on the role of Th17 cells and IL-27 in the regulation of immune reactions in non-small-cell lung cancer (NSCLC). The aim of this study is to assess the variation of Th17 cells and IL-27 in the peripheral blood (PB) of patients with NSCLC. The proportion of Th17 cells in peripheral blood mononuclear cells (PBMCs) was evaluated by flow cytometry. The serum concentrations of IL-27 and IL-17 were measured by enzyme-linked immunosorbent assay (ELISA). The mRNA expression of RORγt and IL-27 in the peripheral blood was examined by real-time quantitative polymerase chain reaction (QPCR). Expression of IL-27 was lower in NSCLC patients compared with normal controls. The frequency of Th17 cells was increased in NSCLC patients, accompanied by the upregulation of IL-17 and RORγt. IL-27 negatively correlated with the number of Th17 cells and the RORγt mRNA. Our results indicate that IL-27 might inhibit Th17 differentiation in NSCLC patients and better understanding of the regulatory effects of IL-27 on Th17 cells may shed light on potential new targets in cancer prevention and therapy.

Cytokeratin-19 fragments, nucleosomes and neuron-specific enolase as early measures of chemotherapy response in non-small cell lung cancer

2012 ◽  
Vol 27 (2) ◽  
pp. 139-146 ◽  
Author(s):  
Mohamed A. Alm El-Din ◽  
Gihan Farouk ◽  
Hala Nagy ◽  
Ayman Abd Elzaher ◽  
Gehan H. Abo El-Magd
Keyword(s):  
Lung Cancer ◽  
Serum Level ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Neuron Specific Enolase ◽  
Small Cell ◽  
Enzyme Linked Immunosorbent Assay ◽  
Cytokeratin 19 ◽  
Small Cell Lung ◽  
Response To Chemotherapy

Aim To investigate the reduction in the serum level of cytokeratin-19 fragments (CYFRA 21–1), nucleosomes and neuron-specific enolase (NSE) as early measures of the response to chemotherapy in non-small cell lung cancer (NSCLC). Methods Forty-two consecutive patients with locally advanced NSCLC were included. All patients received platinum-based chemotherapy. Staging investigations and quantification of CYFRA 21–1, nucleosomes and NSE (using enzyme-linked immunosorbent assay, ELISA) were performed before the start of treatment and after the second cycle of chemotherapy. According to the response to chemotherapy, patients were classified into 3 groups: (I) disease regression, (II) stable disease, and (III) progressive disease. The reduction in the levels of tumor markers was correlated with the response to chemotherapy. Results After the second cycle of chemotherapy, groups I and II had significantly decreased serum levels of CYFRA 21–1 (p<0.05). Similarly, the concentration of nucleosomes was significantly lower than the baseline levels in groups I (p=0.0008) and II (p=0.003). The reduction of both CYFRA 21–1 and nucleosome levels was not significant for patients in group III. In all groups the reduction of NSE levels in response to chemotherapy was not significant. As a marker of response to chemotherapy, CYFRA 21–1 showed the highest sensitivity (88.9%) and specificity (77.4%) compared with nucleosomes (77.8% and 58.1% respectively) and NSE (66.7% and 51.8% respectively). Conclusion The reduction in the serum level of CYFRA 21–1 and nucleosomes may be used for early identification of NSCLC patients with good response to chemotherapy.

Tumor-suppressive activity of sTRAIL on circulating CD44+ cells in patients with non-small cell lung cancer

2020 ◽  
Vol 401 (3) ◽  
pp. 417-422 ◽  
Author(s):  
Yan-Bin Sun ◽  
Guang-Hao Sun ◽  
Shun Xu ◽  
Jing-Jing Xu
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Enzyme Linked Immunosorbent Assay ◽  
Small Cell Lung ◽  
Healthy Control ◽  
Nsclc Patients

AbstractCirculating CD44+ cells have been identified as a prognostic marker for patients with non-small cell lung cancer (NSCLC). Serum tumor necrosis factor-related apoptosis-inducing ligand (sTRAIL) is involved in the pathophysiology of many cancers. However, no previous studies have shown the roles of sTRAIL in circulating CD44+ cells in the blood of NSCLC patients. We detected circulating CD44+ cells and sTRAIL levels in blood samples from NSCLC patients using flow cytometry and an enzyme-linked immunosorbent assay (ELISA). Anti-tumor roles of TRAIL in CD44+ cells were confirmed using a CCK-8 assay and mouse models. A higher number of circulating CD44+ cells were identified in NSCLC patients compared with healthy control individuals. In addition, we confirmed the anti-tumor roles and mechanisms of TRAIL in CD44+ cells both in vitro and in vivo. Our results indicate that (1) there is a negative correlation between sTRAIL and circulating CD44+ cells in NSCLC patients and (2) CD44+ cells have cancer stem cell properties and are more sensitive than CD44− cells to TRAIL.

Sign in / Sign up

Export Citation Format

Share Document